Biotricity(BTCY)

Focus: Biotricity develops remote cardiac monitoring devices and health management software for cardiovascular disease management. The company operates as a public biotech firm with modest revenue scale ($12M FY2025) focused on digital health in cardiology.

Cardiovascular

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Biotricity

AI assessmentNot Hiring

No open roles listed right now. Follow Biotricity to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$12M

FY2025

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

SEC Filings: 2 available

Financials (FY2025)

Revenue

Help build intelligence for Biotricity

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage medical device/digital health company with public market validation (NASDAQ: BTCY)
Focused niche in remote cardiac monitoring with growing clinical adoption potential
Lean R&D spend (21% of revenue) suggests lean operational model

Watch Out For

Severe cash burn ($14.1M loss FY2025) with critically low cash reserves ($786K) indicates imminent funding pressure or restructuring risk
No active clinical trials, no published research, and no active job openings suggest organizational contraction
Revenue growth stalled (only +20% YoY to $12M) with negative profitability trajectory worsening year-over-year

Generated by Claude from Biotricity's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

R&D Spend

$3M(21%)20%

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo